News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sirtris Pharmaceuticals (SIRT) Completes Exclusive License to Harvard University's SIRT3-Based Intellectual Property



9/16/2008 9:18:23 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris, a GSK Company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it has completed an agreement with Harvard University to exclusively license two patent applications covering SIRT3-based methods of treatments and assays.

Read at press release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES